Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasite motility, essential for survival and infection, is regulated by cholinergic signaling. Anticholinergic drugs disrupt this signaling by blocking acetylcholine receptors, leading to reduced motility or paralysis. This mechanism is explored as a therapeutic strategy against parasitic infections, targeting neuromuscular function in helminths and protozoa.
Anticholinergic drugs inhibit parasite motility by antagonizing cholinergic receptors (mAChRs and nAChRs), disrupting neuromuscular transmission and causing paralysis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite Motility (Anticholinergic Effect).